Rani Therapeutics (NASDAQ:RANI – Get Free Report) had its price target raised by equities researchers at BTIG Research from $7.00 to $14.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s price objective indicates a potential upside of 106.49% from the company’s previous close.
A number of other equities analysts also recently commented on RANI. HC Wainwright raised their price objective on Rani Therapeutics from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday. Canaccord Genuity Group dropped their price objective on shares of Rani Therapeutics from $21.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday, March 27th. Finally, Wedbush reaffirmed an “outperform” rating and set a $8.00 price target on shares of Rani Therapeutics in a research report on Tuesday, February 6th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Rani Therapeutics currently has a consensus rating of “Buy” and an average target price of $12.20.
View Our Latest Analysis on Rani Therapeutics
Rani Therapeutics Trading Down 5.2 %
Rani Therapeutics (NASDAQ:RANI – Get Free Report) last announced its quarterly earnings data on Wednesday, March 20th. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.04. On average, research analysts anticipate that Rani Therapeutics will post -0.94 earnings per share for the current fiscal year.
Rani Therapeutics Company Profile
Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.
Further Reading
- Five stocks we like better than Rani Therapeutics
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Roblox: The Bottom Just Fell Out of the Metaverse
- How to invest in marijuana stocks in 7 steps
- Airbnb Stock Plummets After Earnings, But is It a Buy?
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Uber’s Earnings Drop Is Investors Opportunity
Receive News & Ratings for Rani Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rani Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.